Pharmacolog divests part of its operations to RaySearch Laboratories AB
Pharmacolog AB (Publ) announces today that the company will divest it's product line Druglog™ to RaySearch Laboratories AB through a so-called asset acquisition. The total value of the transaction amounts to SEK 8.5 million, of which the cash consideration is SEK 7 million , which will be paid at the time of the closing. Through this transaction, Druglog™ gains new and better conditions to develop commercially within RaySearch, for the benefit of cancer patients and healthcare providers worldwide.During the fourth quarter of 2024, the Board of Directors of Pharmacolog implemented a strategy